- Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.
Tags: Lymphoma, Immunotherapy
- The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study by researchers at Dana-Farber Cancer.
Tags: BasicResearch, MultipleMyeloma
- The Leapfrog Group has named Dana-Farber Cancer Institute to its annual list of Top Hospitals for the first time.
Tags: Honors, PatientSafety
- Fifty-seven physicians and surgeons affiliated with Dana-Farber have been named to Boston magazine's annual "Top Doctors" guide.
- Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.
Tags: Melanoma, Immunotherapy
- Three Dana-Farber Cancer Institute faculty are named Fellows of the American Association for the Advancement of Science (AAAS).
Tags: Appointments, Honors
- Scientists will be better able to trace how genetic changes give rise to diseases ranging from cancer to Huntington’s disease with a new map of protein-protein interactions within human cells produced by researchers at the Center for Cancer Systems Biology (CCSB) at Dana-Farber and associates around the world.
Tags: Genomics, Genetics
- A research team led by Dana-Farber Cancer Institute and Brigham and Women’s Hospital has uncovered surprising new findings that underscore the role of an important signaling pathway, already known to be critical in cancer, in the development of type 2 diabetes.
- In a major advance in the care of patients with leukemia and other blood disorders, physicians at Dana-Farber/Brigham and Women's Cancer Center have begun using Rapid Heme Panel, a high-tech genetic test that provides, within a matter of days, an unprecedented amount of critical information to aid the choice of treatment.
Tags: StemCellTransplant, TranslationalResearch, Leukemia
- Researchers have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells by turning the protein's own molecular machinations against it. In a study published online by the journal Cell, the scientists used a specially crafted compound to disrupt the protein's ability to rev up its own production and that of other proteins involved in tumor cell growth.
Tags: ChildhoodCancer, TargetedTherapy, TranscriptionFactors
Showing 31-40 of 578 items